Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the ‘age of remission’?

Bibliography

• World Health Organization (WHO). Chronic rheumatic conditions. Available from: http://www who int/chp/topics/rheumatic/ en/print html [Cited 14 May 2009]
   Google Scholar
• Symmons DP, Barrett EM, Bankhead CR, The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735-9
   PubMedGoogle Scholar
• Royal College of Physicians and National Institute for Health and Clinical Excellence (NICE). Rheumatoid arthritis 2009: national clinical guideline for management and treatment in adults. London: Royal College of Physicians, 2009
   Google Scholar
• Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK general practice research database. J Rheumatol 2003;30:1196-202
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE). Rheumatoid arthritis consultation document 2006. Available from: http://www nice org uk/nicemedia/pdf/scope_ra_consultation pdf [Cited 14 May 2009]
   Google Scholar
• Goodson NJ, Farragher TM, Symmons DP. Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis. J Rheumatol 2008;35:945-9
   PubMed Web of Science ®Google Scholar
• Walsh NC, Crotti TN, Goldring SR, Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005;208:228-51
   PubMed Web of Science ®Google Scholar
• Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88
   PubMed Web of Science ®Google Scholar
• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61
   PubMed Web of Science ®Google Scholar
• Nemeth E, Rivera S, Gabayan V, IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6
   PubMed Web of Science ®Google Scholar
• Raj DS. Role of Interleukin-6 in the Anemia of chronic disease. Semin Arthritis Rheum 2008;38:382-8
   PubMed Web of Science ®Google Scholar
• Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:907-27
   PubMed Web of Science ®Google Scholar
• Yoshizaki K, Nishimoto N, Mihara M, Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998;20:247-59
   PubMed Web of Science ®Google Scholar
• Nannini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:340-6
   PubMed Web of Science ®Google Scholar
• del Rincon ID, Williams K, Stern MP, High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43
   PubMed Web of Science ®Google Scholar
• Farragher TM, Goodson NJ, Naseem H, Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008;58:359-69
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74
   PubMed Web of Science ®Google Scholar
• Luqmani R, Hennell S, Estrach C, British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 2006;45:1167-9
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90
   PubMed Web of Science ®Google Scholar
• Voll RE, Kalden JR. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Ann NY Acad Sci 2005;1051:799-810
   PubMed Web of Science ®Google Scholar
• Choy E. Clinical experience with inhibition of interleukin-6. Rheum Dis Clin North Am 2004;30:405-15, viii
   PubMed Web of Science ®Google Scholar
• Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357-68
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Haan S, Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20
   PubMed Web of Science ®Google Scholar
• Straub RH, Muller-Ladner U, Lichtinger T, Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol 1997;36:1298-303
   PubMedGoogle Scholar
• Robak T, Gladalska A, Stepien H, Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 1998;7:347-53
   PubMed Web of Science ®Google Scholar
• Jones SA, Richards PJ, Scheller J, IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005;25:241-53
   PubMed Web of Science ®Google Scholar
• Romano M, Sironi M, Toniatti C, Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315-25
   PubMed Web of Science ®Google Scholar
• Lally F, Smith E, Filer A, A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum 2005;52:3460-9
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8
   PubMed Web of Science ®Google Scholar
• Kudo O, Sabokbar A, Pocock A, Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7
   PubMed Web of Science ®Google Scholar
• Kotake S, Sato K, Kim KJ, Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11:88-95
   PubMed Web of Science ®Google Scholar
• Nakahara H, Song J, Sugimoto M, Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003;48:1521-9
   PubMed Web of Science ®Google Scholar
• Depraetere S, Willems J, Joniau M. Stimulation of CRP secretion in HepG2 cells: cooperative effect of dexamethasone and interleukin 6. Agents Actions 1991;34:369-75
   PubMedGoogle Scholar
• Khovidhunkit W, Kim MS, Memon RA, Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169-96
   PubMed Web of Science ®Google Scholar
• Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002;4:R5
   PubMedGoogle Scholar
• Woods A, Brull DJ, Humphries SE, Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000;21:1574-83
   PubMed Web of Science ®Google Scholar
• Georgiadis AN, Papavasiliou EC, Lourida ES, Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment–a prospective, controlled study. Arthritis Res Ther 2006;8:R82
   PubMed Web of Science ®Google Scholar
• Voulgari PV, Kolios G, Papadopoulos GK, Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 1999;92:153-60
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Peeters HR, Rozemuller H, IL-6-induced anaemia in rats: possible pathogenetic implications for anemia observed in chronic inflammations. Clin Exp Immunol 1996;103:328-34
   PubMed Web of Science ®Google Scholar
• Cutolo M, Foppiani L, Minuto F. Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J Endocrinol Invest 2002;25:19-23
   PubMedGoogle Scholar
• Mastorakos G, Ilias I. Relationship between interleukin-6 (IL-6) and hypothalamic-pituitary-adrenal axis hormones in rheumatoid arthritis. Z Rheumatol 2000;59(Suppl 2):II/75-9
   Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Muller-Newen G, Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334(Pt 2):297-314
   PubMed Web of Science ®Google Scholar
• Rose-John S, Scheller J, Elson G, Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-36
   PubMed Web of Science ®Google Scholar
• Ohsugi Y, Kishimoto T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2008;8:669-81
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K, Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003;30:1426-35
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Efficacy and safety of tocilizumab in monotherapy, an anti-IL-6 receptor monoclonal antibody, in patients with active rheumatoid arthritis: results from a 24 week double-blind phase III study. Ann Rheum Dis 2006;65:59 [abstract]
   Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, L-6 Receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre Randomised Placebo Controlled Trial. Ann Rheum Dis 2008;67:1516-23
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Fairfax MJ, Pavelka K, Targeted inhibition of IL-6 signalling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs. American College of Rheumatology (ACR) Congress, 6 – 11 November in Boston, US 2007 [abstract L6]
   Google Scholar
• Genovese M, McKay J, Nasonov E, IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: the TOWARD study. American College of Rheumatology (ACR) Congress, 6 – 11 November in Boston, US 2007 [abstract L15]
   Google Scholar
• Gomez-Reino JJ, Nasonov EL, McKay JD, The TOWARD trial: significant and rapid reduction in disease activity with tocilizumab in combination with six different DMARDs in patients with RA having inadequately response to DMARDs. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, 11 – 14 June in Paris, France 2008 [abstract THU0180]
   Google Scholar
• Jones G, Lowenstein M, Calvo A, Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis: the AMBITION study. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, 11 – 14 June in Paris, France 2008 [abstract OP-0131]
   Google Scholar
• Genovese MC, McKay JD, Nasonov EL, Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80
   PubMed Web of Science ®Google Scholar
• Sebba A, Calvo A, Lowenstein M, Tocilizumab monotherapy improves quality of life compared with methotrexate monotherapy in patients with rheumatoid arthritis: the AMBITION study. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, 11 – 14 June in Paris, France 2008 [abstract FRI0174]
   Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Three-year extension of the SAMURAI study confirms tocilizumab to prevent joint destruction in patients with rheumatoid arthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, 11 – 14 June in Paris, France 2008 [abstract FRI0153]
   Google Scholar
• Kremer JM, Fleischmann RM, Halland A-M, Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study (L14). American College of Rheumatology (ACR) Congress, October in San Francisco, US 2008;24-9 [abstract L14]
   Google Scholar
• van Vollenhoven R, Smolen J, Tony HP, Safety of Tocilizumab in patients with rheumatoid arthritis: an interim analysis of long-term extension trials with a mean treatment duration of 1.5 years (1670). American College of Rheumatology (ACR) Congress, October in San Francisco 2008;24-9 [abstract 1670]
   Google Scholar
• Kremer J, van Vollenhoven R, Ridley DJ, Relationship between patient characteristics and the development of serious infections in patients receiving tocilizumab: results from long-term extension studies with a follow-up duration of 1.5 years (1668). American College of Rheumatology (ACR) Congress, October in San Francisco, US 2008;24-9 [abstract 1668]
   Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602
   PubMed Web of Science ®Google Scholar
• van der HD, Klareskog L, Rodriguez-Valverde V, Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
   PubMed Web of Science ®Google Scholar
• Allanore Y, Kahan A, Sellam J, Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 2006;365:143-8
   PubMed Web of Science ®Google Scholar
• Seriolo B, Paolino S, Sulli A, Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 2006;1069:414-9
   PubMed Web of Science ®Google Scholar
• Wallenius V, Wallenius K, Ahrén B, Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75-9
   PubMed Web of Science ®Google Scholar
• Cressman DE, Greenbaum LE, DeAngelis RA, Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996;274:1379-83
   PubMed Web of Science ®Google Scholar
• Trautwein C, Rakemann T, Niehof M, Acute-phase response factor, increased binding, and target gene transcription during liver regeneration. Gastroenterology 1996;110:1854-62
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6
   PubMed Web of Science ®Google Scholar
• Ehrenstein MR, Evans JG, Singh A, Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy. J Exp Med 2004;200:277-85
   PubMed Web of Science ®Google Scholar